Exelixis Notches Win Against MSN In Cancer Drug Patent Trial
IP Law 360
JANUARY 19, 2023
A Delaware federal judge on Thursday rejected MSN Laboratories' validity challenge to a patent on Exelixis Inc.'s s blockbuster cancer drug Cabometyx, potentially keeping MSN's planned generic version off the market until 2026, while clearing the company of infringing a second patent.
75 
Let's personalize your content